{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:13:53Z","timestamp":1790648033853,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23fk0108590"],"award-info":[{"award-number":["JP23fk0108590"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25fk0310525"],"award-info":[{"award-number":["JP25fk0310525"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0108427"],"award-info":[{"award-number":["JP21fk0108427"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0108660"],"award-info":[{"award-number":["JP24fk0108660"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0108660"],"award-info":[{"award-number":["JP24fk0108660"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-08494-x","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T18:55:09Z","timestamp":1752864909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bivalent single-domain antibodies show potent mpox virus neutralization through M1R antigen"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-6776","authenticated-orcid":false,"given":"Daisuke","family":"Akazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5745-8413","authenticated-orcid":false,"given":"Masayuki","family":"Shimojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Sil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Okutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8357-2498","authenticated-orcid":false,"given":"Milagros","family":"Virhuez-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hishiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-5439","authenticated-orcid":false,"given":"Ken","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2576-9735","authenticated-orcid":false,"given":"Hideki","family":"Ebihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6342-4087","authenticated-orcid":false,"given":"Yoshimasa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-9966","authenticated-orcid":false,"given":"Koichi","family":"Watashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"8494_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/d41586-022-01421-8","volume":"606","author":"M Kozlov","year":"2022","unstructured":"Kozlov, M. Monkeypox goes global: why scientists are on alert. Nature 606, 15\u201316 (2022).","journal-title":"Nature"},{"key":"8494_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa2207323","volume":"387","author":"JP Thornhill","year":"2022","unstructured":"Thornhill, J. P. et al. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. N. Engl. J. Med. 387, 679\u2013691 (2022).","journal-title":"N. Engl. J. Med."},{"key":"8494_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.medj.2022.06.002","volume":"3","author":"BK Titanji","year":"2022","unstructured":"Titanji, B. K. Neglecting emerging diseases - monkeypox is the latest price of a costly default. Med 3, 433\u2013434 (2022).","journal-title":"Med"},{"key":"8494_CR4","unstructured":"WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. 2022. Available from: https:\/\/www.who.int\/azerbaijan\/news\/item\/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern."},{"key":"8494_CR5","unstructured":"WHO 2022-24 Mpox (Monkeypox) Outbreak: Global Trends. 2024. Available from: https:\/\/worldhealthorg.shinyapps.io\/mpx_global\/."},{"key":"8494_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010141","volume":"16","author":"EM Bunge","year":"2022","unstructured":"Bunge, E. M. et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl. Trop. Dis. 16, e0010141 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"8494_CR7","unstructured":"Vakaniaki, E. H. et al. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. Nat. Med. (2024)."},{"key":"8494_CR8","unstructured":"WHO Mpox (monkeypox) \u2013 Democratic Republic of the Congo. 2023. Available from: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2023-DON493."},{"key":"8494_CR9","unstructured":"WHO Director-General declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern. 2024. Available from: https:\/\/www.who.int\/news\/item\/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern."},{"key":"8494_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/jac\/dku545","volume":"70","author":"S Duraffour","year":"2015","unstructured":"Duraffour, S. et al. ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping. J. Antimicrob. Chemother. 70, 1367\u20131380 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"8494_CR11","first-page":"e00927","volume":"6","author":"CL Hutson","year":"2021","unstructured":"Hutson, C. L. et al. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. mSphere 6, e00927 (2021).","journal-title":"mSphere"},{"key":"8494_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.antiviral.2007.08.003","volume":"77","author":"S Parker","year":"2008","unstructured":"Parker, S. et al. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antivir. Res. 77, 39\u201349 (2008).","journal-title":"Antivir. Res."},{"key":"8494_CR13","unstructured":"CDC Clinical Treatment of Mpox. 2025. Available from: https:\/\/www.cdc.gov\/mpox\/hcp\/clinical-care\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/poxvirus\/mpox\/clinicians\/treatment.html."},{"key":"8494_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","volume":"239","author":"B Moss","year":"2011","unstructured":"Moss, B. Smallpox vaccines: targets of protective immunity. Immunol. Rev. 239, 8\u201326 (2011).","journal-title":"Immunol. Rev."},{"key":"8494_CR15","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cell.2016.09.049","volume":"167","author":"I Gilchuk","year":"2016","unstructured":"Gilchuk, I. et al. Cross-neutralizing and protective human antibody specificities to Poxvirus Infections. Cell 167, 684\u201394.e9 (2016).","journal-title":"Cell"},{"key":"8494_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01598-23","volume":"11","author":"T Noy-Porat","year":"2023","unstructured":"Noy-Porat, T. et al. Generation of recombinant mAbs to vaccinia virus displaying high affinity and potent neutralization. Microbiol. Spectr. 11, e0159823 (2023).","journal-title":"Microbiol. Spectr."},{"key":"8494_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47328-y","volume":"15","author":"H Tamir","year":"2024","unstructured":"Tamir, H. et al. Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection. Nat. Commun. 15, 3265 (2024).","journal-title":"Nat. Commun."},{"key":"8494_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35642-2","volume":"13","author":"M Li","year":"2022","unstructured":"Li, M. et al. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4\/5 and diverse sarbecoviruses. Nat. Commun. 13, 7957 (2022).","journal-title":"Nat. Commun."},{"key":"8494_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/IJN.S387160","volume":"18","author":"Y Lu","year":"2023","unstructured":"Lu, Y. et al. Multivalent and thermostable nanobody neutralizing SARS-CoV-2 Omicron (B.1.1.529). Int. J. Nanomed. 18, 353\u2013367 (2023).","journal-title":"Int. J. Nanomed."},{"key":"8494_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41594-020-0469-6","volume":"27","author":"J Huo","year":"2020","unstructured":"Huo, J. et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat. Struct. Mol. Biol. 27, 846\u2013854 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"8494_CR21","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.abe3255","volume":"370","author":"M Schoof","year":"2020","unstructured":"Schoof, M. et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 370, 1473\u20131479 (2020).","journal-title":"Science"},{"key":"8494_CR22","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1126\/science.abe4747","volume":"370","author":"Y Xiang","year":"2020","unstructured":"Xiang, Y. et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science 370, 1479\u20131484 (2020).","journal-title":"Science"},{"key":"8494_CR23","first-page":"787","volume":"13","author":"N Tomita","year":"2023","unstructured":"Tomita, N. et al. Evaluating the immunogenicity and safety of a smallpox vaccine to monkeypox in healthy Japanese adults: a single-arm study. Life (Basel) 13, 787 (2023).","journal-title":"Life (Basel)"},{"key":"8494_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003563","volume":"9","author":"TH Chang","year":"2013","unstructured":"Chang, T. H. et al. Crystal structure of vaccinia viral A27 protein reveals a novel structure critical for its function and complex formation with A26 protein. PLoS Pathog. 9, e1003563 (2013).","journal-title":"PLoS Pathog."},{"key":"8494_CR25","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1128\/JVI.02247-09","volume":"84","author":"HP Su","year":"2010","unstructured":"Su, H. P. et al. The structure of the poxvirus A33 protein reveals a dimer of unique C-type lectin-like domains. J. Virol. 84, 2502\u20132510 (2010).","journal-title":"J. Virol."},{"key":"8494_CR26","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.cell.2024.01.017","volume":"187","author":"A Zuiani","year":"2024","unstructured":"Zuiani, A. et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell 187, 1363\u201373.e12 (2024).","journal-title":"Cell"},{"key":"8494_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48312-2","volume":"15","author":"R Zhao","year":"2024","unstructured":"Zhao, R. et al. Two noncompeting human neutralizing antibodies targeting MPXV B6 show protective effects against orthopoxvirus infections. Nat. Commun. 15, 4660 (2024).","journal-title":"Nat. Commun."},{"key":"8494_CR28","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.virol.2008.12.019","volume":"385","author":"CH Foo","year":"2009","unstructured":"Foo, C. H. et al. Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans. Virology 385, 368\u2013382 (2009).","journal-title":"Virology"},{"key":"8494_CR29","doi-asserted-by":"publisher","first-page":"8687","DOI":"10.1128\/JVI.00852-08","volume":"82","author":"H Bisht","year":"2008","unstructured":"Bisht, H. et al. Vaccinia virus l1 protein is required for cell entry and membrane fusion. J. Virol. 82, 8687\u20138694 (2008).","journal-title":"J. Virol."},{"key":"8494_CR30","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/vaccines12080846","volume":"12","author":"P Huang","year":"2024","unstructured":"Huang, P. et al. A Pseudovirus nanoparticle displaying the Vaccinia Virus L1 protein elicited high neutralizing antibody titers and provided complete protection to mice against mortality caused by a Vaccinia virus challenge. Vaccines 12, 846 (2024).","journal-title":"Vaccines"},{"key":"8494_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2401931","volume":"13","author":"Z Ren","year":"2024","unstructured":"Ren, Z. et al. Identification of mpox M1R and B6R monoclonal and bispecific antibodies that efficiently neutralize authentic mpox virus. Emerg. Microbes Infect. 13, 2401931 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"8494_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/jacsau.0c00037","volume":"1","author":"SL Regen","year":"2021","unstructured":"Regen, S. L. Membrane-disrupting molecules as therapeutic agents: a cautionary note. JACS Au 1, 3\u20137 (2021).","journal-title":"JACS Au"},{"key":"8494_CR33","doi-asserted-by":"publisher","first-page":"7173","DOI":"10.2147\/IJN.S431619","volume":"18","author":"N Meng","year":"2023","unstructured":"Meng, N. et al. Screening, expression and identification of nanobody against Monkeypox Virus A35. R. Int. J. Nanomed. 18, 7173\u20137181 (2023).","journal-title":"R. Int. J. Nanomed."},{"key":"8494_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106263","volume":"9","author":"SA Walper","year":"2014","unstructured":"Walper, S. A. et al. Development and evaluation of single domain antibodies for vaccinia and the L1 antigen. PLoS One 9, e106263 (2014).","journal-title":"PLoS One"},{"key":"8494_CR35","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.3390\/molecules28196838","volume":"28","author":"H Yu","year":"2023","unstructured":"Yu, H. et al. In vitro affinity maturation of nanobodies against Mpox Virus A29 protein based on computer-aided design. Molecules 28, 6838 (2023).","journal-title":"Molecules"},{"key":"8494_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41421-025-00771-7","volume":"11","author":"X Yang","year":"2025","unstructured":"Yang, X. et al. Identification of neutralizing nanobodies protecting against poxvirus infection. Cell Discov. 11, 31 (2025).","journal-title":"Cell Discov."},{"key":"8494_CR37","doi-asserted-by":"publisher","first-page":"100859","DOI":"10.1016\/S2666-5247(24)00074-0","volume":"5","author":"I Moraes-Cardoso","year":"2024","unstructured":"Moraes-Cardoso, I. et al. Immune responses associated with mpox viral clearance in men with and without HIV in Spain: a multisite, observational, prospective cohort study. Lancet Microbe 5, 100859 (2024).","journal-title":"Lancet Microbe"},{"key":"8494_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s43856-024-00443-9","volume":"4","author":"F Chiuppesi","year":"2024","unstructured":"Chiuppesi, F. et al. Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus. Commun. Med.4, 19 (2024).","journal-title":"Commun. Med."},{"key":"8494_CR39","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/S1473-3099(23)00352-3","volume":"23","author":"H Cohn","year":"2023","unstructured":"Cohn, H. et al. Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study. Lancet Infect. Dis. 23, 1302\u20131312 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"8494_CR40","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/infdis\/jiad058","volume":"228","author":"D Akazawa","year":"2023","unstructured":"Akazawa, D. et al. Potential Anti-Mpox virus activity of Atovaquone, Mefloquine, and Molnupiravir, and their potential use as treatments. J. Infect. Dis. 228, 591\u2013603 (2023).","journal-title":"J. Infect. Dis."},{"key":"8494_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00566-23","volume":"11","author":"T Hishiki","year":"2023","unstructured":"Hishiki, T. et al. Identification of IMP Dehydrogenase as a potential target for anti-Mpox Virus agents. Microbiol. Spectr. 11, e0056623 (2023).","journal-title":"Microbiol. Spectr."},{"key":"8494_CR42","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1099\/vir.0.010207-0","volume":"90","author":"M Saijo","year":"2009","unstructured":"Saijo, M. et al. Virulence and pathophysiology of the Congo Basin and West African strains of monkeypox virus in non-human primates. J. Gen. Virol. 90, 2266\u20132271 (2009).","journal-title":"J. Gen. Virol."},{"key":"8494_CR43","doi-asserted-by":"publisher","first-page":"e16228","DOI":"10.7554\/eLife.16228","volume":"5","author":"S Moutel","year":"2016","unstructured":"Moutel, S. et al. NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. Elife 5, e16228 (2016).","journal-title":"Elife"},{"key":"8494_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jviromet.2011.05.002","volume":"175","author":"SN Shchelkunov","year":"2011","unstructured":"Shchelkunov, S. N. et al. Species-specific identification of variola, monkeypox, cowpox, and vaccinia viruses by multiplex real-time PCR assay. J. Virol. Method 175, 163\u2013169 (2011).","journal-title":"J. Virol. Method"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08494-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08494-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08494-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:40:35Z","timestamp":1757256035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08494-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8494"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-08494-x","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1073"}}